NPS Pharmaceuticals

NPS Pharmaceuticals is a global biopharmaceutical company that focuses on developing innovative treatments for rare diseases, such as Short Bowel Syndrome and Hypoparathyroidism. The company was founded in 1986 by Tony Coles and is headquartered in Bedminster, New Jersey, with key people including Francois Nader and Luke M. Beshar. NPS Pharmaceuticals has collaborations with various organizations, including Shire plc, Takeda Pharmaceutical Company, and GlaxoSmithKline, to develop and commercialize its products, such as Gattex and Natpara, which have received approvals from regulatory agencies like the US Food and Drug Administration and the European Medicines Agency.

● History

NPS Pharmaceuticals was founded in 1986 by Tony Coles, with the goal of developing innovative treatments for rare diseases, such as Short Bowel Syndrome and Hypoparathyroidism. The company has its roots in Salt Lake City, Utah, where it was initially headquartered, before moving to Bedminster, New Jersey. Over the years, NPS Pharmaceuticals has undergone significant transformations, including the appointment of Francois Nader as its CEO in 2006, who has played a crucial role in shaping the company's strategy and direction, including collaborations with Shire plc, Takeda Pharmaceutical Company, and GlaxoSmithKline. The company has also received funding from investors like Frazier Healthcare Ventures, OrbiMed Advisors, and New Enterprise Associates, which has enabled it to advance its research and development programs, including those focused on Gastroenterology and Endocrinology.

● Products

NPS Pharmaceuticals has developed several products, including Gattex, a treatment for Short Bowel Syndrome, and Natpara, a treatment for Hypoparathyroidism. These products have received approvals from regulatory agencies like the US Food and Drug Administration and the European Medicines Agency, and are marketed in collaboration with partners like Shire plc and Takeda Pharmaceutical Company. The company's products are designed to address the unmet medical needs of patients with rare diseases, and have been recognized by organizations like the National Organization for Rare Disorders and the European Organisation for Rare Diseases. NPS Pharmaceuticals' products have also been studied in clinical trials conducted at institutions like Harvard University, Stanford University, and University of California, Los Angeles, which have demonstrated their safety and efficacy in treating rare diseases.

● Research and Development

NPS Pharmaceuticals has a strong research and development program, focused on developing innovative treatments for rare diseases, such as Short Bowel Syndrome and Hypoparathyroidism. The company has collaborations with various academic institutions, including Harvard University, Stanford University, and University of California, Los Angeles, to advance its research programs, which are led by scientists like Dr. Roger Garceau and Dr. Scott Stromatt. NPS Pharmaceuticals is also a member of industry organizations like the Biotechnology Innovation Organization and the National Biotechnology Council, which provide a platform for the company to engage with other stakeholders in the biotechnology industry, including companies like Amgen, Gilead Sciences, and Celgene. The company's research and development programs are focused on developing new treatments for rare diseases, and have been recognized by awards like the Prix Galien and the Albany Medical Center Prize in Medicine and Biomedical Research.

● Corporate Affairs

NPS Pharmaceuticals is a publicly traded company, listed on the NASDAQ stock exchange, with a market capitalization of over $2 billion. The company has a strong leadership team, including Francois Nader and Luke M. Beshar, who have played a crucial role in shaping the company's strategy and direction, including collaborations with Shire plc, Takeda Pharmaceutical Company, and GlaxoSmithKline. NPS Pharmaceuticals has also received funding from investors like Frazier Healthcare Ventures, OrbiMed Advisors, and New Enterprise Associates, which has enabled it to advance its research and development programs, including those focused on Gastroenterology and Endocrinology. The company is headquartered in Bedminster, New Jersey, and has operations in the United States, Europe, and Asia, with partners like Pfizer, Merck & Co., and AstraZeneca.

● Acquisitions and Merger

In 2015, NPS Pharmaceuticals was acquired by Shire plc for $5.2 billion, in a deal that was announced in January 2015 and completed in February 2015. The acquisition was seen as a strategic move by Shire plc to expand its portfolio of rare disease treatments, and to strengthen its position in the biotechnology industry, with companies like Biogen, Gilead Sciences, and Celgene. The acquisition also marked a significant milestone for NPS Pharmaceuticals, which had been a publicly traded company since 2004, with listings on the NASDAQ stock exchange. Following the acquisition, NPS Pharmaceuticals' products, including Gattex and Natpara, became part of Shire plc's portfolio, and are now marketed and distributed by Shire plc's global commercial organization, with partners like Takeda Pharmaceutical Company and GlaxoSmithKline. The acquisition has also enabled Shire plc to expand its research and development programs, including those focused on Gastroenterology and Endocrinology, with collaborations with academic institutions like Harvard University, Stanford University, and University of California, Los Angeles.